These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

852 related items for PubMed ID: 25069030

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Time Course and Clinical Implications of Development of Antibodies Against Adalimumab in Patients With Inflammatory Bowel Disease.
    Steenholdt C, Frederiksen MT, Bendtzen K, Ainsworth MA, Thomsen OØ, Brynskov J.
    J Clin Gastroenterol; 2016 Jul; 50(6):483-9. PubMed ID: 26166141
    [Abstract] [Full Text] [Related]

  • 4. Influence of combination therapy with immune modulators on anti-TNF trough levels and antibodies in patients with IBD.
    van Schaik T, Maljaars JP, Roopram RK, Verwey MH, Ipenburg N, Hardwick JC, Veenendaal RA, van der Meulen-de Jong AE.
    Inflamm Bowel Dis; 2014 Dec; 20(12):2292-8. PubMed ID: 25230167
    [Abstract] [Full Text] [Related]

  • 5. Changes in serum trough levels of infliximab during treatment intensification but not in anti-infliximab antibody detection are associated with clinical outcomes after therapeutic failure in Crohn's disease.
    Steenholdt C, Bendtzen K, Brynskov J, Thomsen OØ, Munck LK, Christensen LA, Pedersen G, Kjeldsen J, Ainsworth MA.
    J Crohns Colitis; 2015 Mar; 9(3):238-45. PubMed ID: 25576753
    [Abstract] [Full Text] [Related]

  • 6. A Genetic Variation in the Neonatal Fc-Receptor Affects Anti-TNF Drug Concentrations in Inflammatory Bowel Disease.
    Billiet T, Dreesen E, Cleynen I, Wollants WJ, Ferrante M, Van Assche G, Gils A, Vermeire S.
    Am J Gastroenterol; 2016 Oct; 111(10):1438-1445. PubMed ID: 27481307
    [Abstract] [Full Text] [Related]

  • 7. Clinical implications of variations in anti-infliximab antibody levels in patients with inflammatory bowel disease.
    Steenholdt C, Al-khalaf M, Brynskov J, Bendtzen K, Thomsen OØ, Ainsworth MA.
    Inflamm Bowel Dis; 2012 Dec; 18(12):2209-17. PubMed ID: 22344964
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Elective switching from infliximab to adalimumab in stable Crohn's disease.
    Hoentjen F, Haarhuis BJ, Drenth JP, de Jong DJ.
    Inflamm Bowel Dis; 2013 Dec; 19(4):761-6. PubMed ID: 23446337
    [Abstract] [Full Text] [Related]

  • 11. Trough levels and antibodies to infliximab may not predict response to intensification of infliximab therapy in patients with inflammatory bowel disease.
    Pariente B, Pineton de Chambrun G, Krzysiek R, Desroches M, Louis G, De Cassan C, Baudry C, Gornet JM, Desreumaux P, Emilie D, Colombel JF, Allez M.
    Inflamm Bowel Dis; 2012 Jul; 18(7):1199-206. PubMed ID: 22127789
    [Abstract] [Full Text] [Related]

  • 12. Quantitative comparison of the neutralizing capacity, immunogenicity and cross-reactivity of anti-TNF-α biologicals and an Infliximab-biosimilar.
    Buurman DJ, Blokzijl T, Festen EAM, Pham BT, Faber KN, Brouwer E, Dijkstra G.
    PLoS One; 2018 Jul; 13(12):e0208922. PubMed ID: 30533022
    [Abstract] [Full Text] [Related]

  • 13. Factors Associated with the Immunogenicity of Anti-Tumor Necrosis Factor Agents in Pediatric Patients with Inflammatory Bowel Disease.
    Kim JY, Lee Y, Choe BH, Kang B.
    Gut Liver; 2021 Jul 15; 15(4):588-598. PubMed ID: 33024062
    [Abstract] [Full Text] [Related]

  • 14. IgE antibodies and skin tests in immediate hypersensitivity reactions to infliximab in inflammatory bowel disease: impact on infliximab retreatment.
    Fréling E, Peyrin-Biroulet L, Poreaux C, Morali A, Waton J, Schmutz JL, Guéant JL, Barbaud A.
    Eur J Gastroenterol Hepatol; 2015 Oct 15; 27(10):1200-8. PubMed ID: 26181108
    [Abstract] [Full Text] [Related]

  • 15. Outcome of pregnancy in women with inflammatory bowel disease treated with antitumor necrosis factor therapy.
    Schnitzler F, Fidder H, Ferrante M, Ballet V, Noman M, Van Assche G, Spitz B, Hoffman I, Van Steen K, Vermeire S, Rutgeerts P.
    Inflamm Bowel Dis; 2011 Sep 15; 17(9):1846-54. PubMed ID: 21830263
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Severe infusion reactions to infliximab: aetiology, immunogenicity and risk factors in patients with inflammatory bowel disease.
    Steenholdt C, Svenson M, Bendtzen K, Thomsen OØ, Brynskov J, Ainsworth MA.
    Aliment Pharmacol Ther; 2011 Jul 15; 34(1):51-8. PubMed ID: 21535447
    [Abstract] [Full Text] [Related]

  • 18. Clinical outcome of adalimumab therapy in patients with ulcerative colitis previously treated with infliximab: a Danish single-center cohort study.
    Christensen KR, Steenholdt C, Brynskov J.
    Scand J Gastroenterol; 2015 Aug 15; 50(8):1018-24. PubMed ID: 25861832
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. A Role for Thiopurine Metabolites in the Synergism Between Thiopurines and Infliximab in Inflammatory Bowel Disease.
    Mogensen DV, Brynskov J, Ainsworth MA, Nersting J, Schmiegelow K, Steenholdt C.
    J Crohns Colitis; 2018 Feb 28; 12(3):298-305. PubMed ID: 29145599
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 43.